Viking Therapeutics: Market Strategists Identify Potential Entry Point

The coming year represents a critical juncture for Viking Therapeutics, a biotechnology firm whose clinical pipeline is drawing significant investor attention. While the company’s financial statements continue to show losses, the focus has shifted decisively to its advancing clinical programs in obesity treatment, prompting a fresh evaluation of its investment potential.

Clinical Pipeline Takes Center Stage

The core of the investment thesis for Viking lies in its drug candidate VK2735. The ongoing Phase 3 trial, known as VANQUISH-1, has already enrolled more than 4,500 participants. Furthermore, the company plans to initiate a Phase 3 study for an oral formulation of VK2735 in the third quarter of 2026. These developments follow the January 2026 publication of Phase 2 data from the VENTURE study, which demonstrated weight reduction of up to 14.7% alongside a favorable safety profile. This tolerability could prove to be a key competitive differentiator against established GLP-1 agonists from rivals like Eli Lilly and Novo Nordisk.

Analyst Sentiment Provides a Tailwind

Recent commentary from financial research firms has injected optimism. On February 27, BTIG Research upgraded its rating for Viking Therapeutics to “Strong Buy.” This move reinforces a generally positive, though not unanimous, view from market observers. Morgan Stanley maintains an “Overweight” rating with a price target of $99, while other institutions advise caution or even recommend selling. The current market consensus sits at a moderate buy recommendation, with an average price target of $87.80.

Should investors sell immediately? Or is it worth buying Viking Therapeutics?

Financial Health and Forthcoming Catalysts

The company’s latest quarterly report in February revealed a larger-than-anticipated loss, with earnings per share at -$1.38 versus estimates of -$0.89. However, its substantial cash reserve of $706 million provides a solid financial runway to advance its clinical agenda. Investor attention is now fixed on upcoming milestones. The management team is scheduled to present at conferences in Miami in March and New York in April. The primary near-term catalysts are the data readouts from the Phase 3 trials and the planned initiation of the oral formulation’s Phase 3 study later this year. Until Viking commercializes a product, its share price will remain heavily dependent on the precise execution of this clinical timeline.

Navigating a Competitive Landscape

Despite promising technological advances, Viking Therapeutics retains the classic risk profile of a pre-revenue biotech company. It operates in a fiercely competitive market and must ultimately prove that its products can achieve both efficacy and commercial success. The current market valuation appears to price in a significant portion of this future potential, which amplifies the downside risk should any clinical setbacks occur. The company is also working to expand its portfolio, with intensive development on a tablet version of its treatment alongside the injectable solution, which could substantially improve its market opportunity. Results from a maintenance dose study are also expected in the third quarter.